Mark C. Markowski
@MarkowskiGUOnc
Followers
655
Following
4K
Media
99
Statuses
527
Genitourinary Oncologist. Associate Professor. Director of GU Oncology in the National Capital Region. Johns Hopkins SKCCC. Views are my own
Washington, DC / Baltimore, MD
Joined October 2016
We’re proud to announce that @US_FDA has granted DeNovo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes in patients with localized prostate cancer: https://t.co/xUf0XObHaQ
0
3
13
Aggies win 8-2 over the Wildcats. Aggies improve to 1-0 and the Wildcats move to 0-1
0
1
3
Very cool - nice work.
Check out our new work exploring AR biology in advanced prostate cancer: https://t.co/SqZKXZ8kcR. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy
1
0
5
Phase 2 trial of single agent rucaparib without ADT in patients with mHSPC who harbor germline mutations in HRR genes. Clinical and objective responses observed. @MarkowskiGUOnc
https://t.co/2McS0Vgg4A
0
2
7
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
https://t.co/CS7SKz6Tuc
8
94
167
Can’t wait to talk about prostate cancer with patients and their caregivers.
Johns Hopkins Kimmel Cancer Center invites you to learn helpful information for treatment advances for metastatic prostate cancer: https://t.co/GGpGl1rfXB
@hopkinskimmel
1
0
5
Congrats to Etan Aber from @nciccr_gmb who lead this effort. Preliminary but provocative retrospective data showing PSA responses with SGLT2 inhibitors in patients with prostate cancer in absence of ADT. https://t.co/L88tK4clc3
1
1
13
Such a pleasure working with @eaonc and @ChrisSweens1. Multimodal AI prostate test by @arteraAI prognostic for OS in patients with mHSPC on CHAARTED trial. Hopeful AI will predict response to treatment as next step. https://t.co/KxFlYBzGLw
1
5
21
@Dr_RaviMadan @HopkinsMedicine @EAntonarakis @davidjeinstein @RPachynski @FatimaKarzai @EdwinPosadasMD @CathyHandy @laurasenamd @MarkowskiGUOnc @mbilusic @Cpaller We would like to inform you that your post has been published on @Oncodaily. Thank you for sharing! https://t.co/Tz3ooQ8u0W
oncodaily.com
PSADTime ≤6 months Identifies High-Risk BRPC Patients after Prostatectomy / Alan W. Partin, Bruce J. Trock, cancer, Daniel L. Suzman, David G.McLeod, Emmanuel
1
1
4
Bigger kid. Bigger fish. Happy Thanksgiving 2024!
0
0
10
Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.
Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer Best data I have seen comes from @HopkinsMedicine team Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos https://t.co/Uu1KGadxTb
1
6
27
Great exchange of ideas and hope to collaborate in the future!@AarmstrongDuke , @MarkowskiGUOnc . Thanks to our Colleagues for your expertise Program for the Multidisciplinary Management of Prostate Cancer held at the National Cancer Institute @incanMX
1
1
6
Just opened a new GU Med Onc position @fredhutch @UWMedicine join our dynamic cohesive team committed to exceptional care, innovative research, mentorship, teaching, DEI, community outreach! https://t.co/zbeF3GsKcu
@nicoleflemingmd @JessicaHawleyMD @HsiehLab @HutchPresident
3
15
54
The Vanderbilt GU Program is looking for new faculty members. Clinical investigators with an interest in translational investigator-initiated trials across GU malignancies are preferred. Message me /@alantanmd for more details! Come work with stellar faculty in an amazing city!
1
21
53
Our haiku about #prostatecancer and the #PCFRetreat24 with @PCFnews by @Freitas_PedroFS @SylvanBacaLab What do you think? 😊 @DrRanaMcKay @EAntonarakis @MarkowskiGUOnc @DrChoueiri @soulehoward1 @AndreaMiyahira @mishabeltran @JoshLangMD
1
3
17
Super excited to see this work from Sangeeta Ray and her group! https://t.co/YAH5POWoHG
@nirmishsingla @cpavmd @michael_gorin @MarkowskiGUOnc @liljasolnes. #PSMA #molecularimaging #theranostics
pubmed.ncbi.nlm.nih.gov
The results suggest that a theranostic strategy targeting PSMA, employing PET and α-emitting radiopharmaceuticals, enabled tumor growth control and enhanced survival in a relevant immunocompetent...
0
1
3
Such an incredibly important ‘negative��� study. Well designed and executed. Excellent job, @DrChoueiri and team
0
1
4
The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or @brian_rini to inquire further. We will also be at #ESMO24
1
19
59
Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations. @JAMAOnc #pcsm #oncology
onclive.com
Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.
0
1
3